Egalet (NASDAQ: EGLT) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
This is a summary of recent ratings for Egalet and Halozyme Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Egalet presently has a consensus target price of $7.10, suggesting a potential upside of 582.69%. Halozyme Therapeutics has a consensus target price of $18.00, suggesting a potential downside of 8.21%. Given Egalet’s stronger consensus rating and higher possible upside, analysts plainly believe Egalet is more favorable than Halozyme Therapeutics.
Volatility and Risk
Egalet has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Insider & Institutional Ownership
54.2% of Egalet shares are held by institutional investors. Comparatively, 84.5% of Halozyme Therapeutics shares are held by institutional investors. 3.8% of Egalet shares are held by company insiders. Comparatively, 16.8% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Egalet and Halozyme Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Egalet and Halozyme Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Egalet||$16.96 million||2.64||-$90.63 million||($3.39)||-0.31|
|Halozyme Therapeutics||$146.69 million||19.03||-$103.02 million||($0.68)||-28.84|
Egalet has higher earnings, but lower revenue than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Egalet, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics beats Egalet on 8 of the 13 factors compared between the two stocks.
Egalet Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.